Dr Martin Hutchings speaks to ecancer about the 5-year update of the ECHELON-1 trial. It is an international, open-label, randomised, phase 3 trial. Initially,
Dr Hutchings mentions the rationale of this study. He then explains the key results from this trial. The ECHELON-1 study assessed the safety and efficacy of front-line A+AVD (brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine) versus ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) in patients with stage III or IV classical Hodgkin lymphoma. The primary analysis showed improved modified progression-free survival with A+AVD. In the end, he talks about the impact of these results on the future treatment of Hodgkin lymphoma.
ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.